Bayer Reports Post-Hoc Data from P-III (ARANOTE) Trial of Nubeqa to Treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Shots:
- Bayer has reported post-hoc analyses from P-III (ARANOTE) trial assessing Nubeqa (darolutamide; 600mg, BID) + androgen deprivation therapy (ADT) (n=446) vs PBO + ADT (n=223) in mHSPC pts (N=669)
- Post-hoc analyses showed that 42.6% pts achieved ultra-low PSA levels (<0.02ng/mL) vs 7.8% pts on PBO & this response was associated with prolonged rPFS, delayed time to mCRPC, & reduced PSA progression; data was presented at AUA 2025
- Previously reported initial data showed improved rPFS (1EP), with 46% reduction in the risk of radiologic progression or death compared to PBO + ADT; data was presented at ESMO 2024 & published in The JCO
Ref: Businesswire | Image: Bayer
Related News:- Bayer's Vitrakvi Receives the US FDA’s Full Approval for NTRK Fusion-Positive Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
